Comprehensive mutational profiling in advanced systemic mastocytosis

Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management

(2012) Animesh Pardanani   AMERICAN JOURNAL OF HEMATOLOGY

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)

(2012) M. Meggendorfer et al.   BLOOD

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

(2012) E. Soucie et al.   BLOOD

High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms

(2012) S. Jeromin et al.   HAEMATOLOGICA

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

(2012) Lambert Busque et al.   NATURE GENETICS

Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis

(2012) Fabiola Traina et al.   PLoS One

EZH2 mutational status predicts poor survival in myelofibrosis

(2011) P. Guglielmelli et al.   BLOOD

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

(2011) K. V. Gleixner et al.   BLOOD

Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay

(2011) Thomas Kristensen et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis

(2011) C Teodosio et al.   LEUKEMIA

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance

(2011) V Grossmann et al.   LEUKEMIA

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis

(2011) Celalettin Ustun et al.   LEUKEMIA RESEARCH

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

(2010) S. Schnittger et al.   BLOOD

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults

(2010) A. Pardanani et al.   BLOOD

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1

(2010) Alexander Kohlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

The 2008 World Health Organization classification system for myeloproliferative neoplasms

(2009) Ayalew Tefferi et al.   CANCER

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera

(2009) S. Schnittger et al.   HAEMATOLOGICA

Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients

(2009) Luis Escribano et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Variable presence ofKITD816Vin clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)

(2009) Karl Sotlar et al.   JOURNAL OF PATHOLOGY

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

(2009) A Tefferi et al.   LEUKEMIA

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis

(2007) Karl Sotlar et al.   JOURNAL OF MOLECULAR DIAGNOSTICS